癌症相关突变对多 (ADP-ribose) 聚合酶1抑制的影响
Neel Shanmugam1, Shubham Chatterjee2, G Andrés Cisneros2,3
1Department of Chemistry, University of North Texas, Denton, TX 76201, USA.
bioRxiv : the preprint server for biology
|November 28, 2024
概括
在V762A变体的Poly (ADP-ribose) 聚合酶1 (PARP1) 结合FDA批准的抑制剂,如talazoparib更有效地. 这种PARP1变体和抑制剂相互作用会影响DNA修复动态和癌细胞亡.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 聚ADP-ribose) 聚合酶1 (PARP1) 对于DNA修复至关重要,其抑制可以诱导癌细胞的亡.
- 这种V762A PARP1变种与各种人类癌症有显著的关联.
- 了解抑制剂与PARP1变体的相互作用是针对癌症向治疗的关键.
研究的目的:
- 为了研究V762A PARP1变异对FDA批准的三种PARP抑制剂:niraparib,rucaparib和talazoparib的抑制的影响.
- 分析这些抑制剂与野生类型 (WT) 和V762A突变PARP1.1的结合 afinities 和分子动力学.
- 阐明 talazoparib 对突变的 PARP1 结构和动态的特定影响.
主要方法:
- 用分子动力学模拟来研究PARP1变体和抑制剂之间的相互作用.
- 进行了具有约束力的自由能量计算,以量化抑制剂的结合.
- 对残留物波动和残留物间相互作用的分析为动态变化提供了洞察力.
主要成果:
- 所有三个抑制剂 (niraparib,rucaparib,talazoparib) 与WT PARP1相比,与V762A PARP1突变体结合的强化,具有类似的结合自由能量.
- 塔拉佐巴里布独特地减少了V762A突变体中的残留物波动,包括关键的催化残留物和终端区域.
- 塔拉佐帕里布还诱导了HD域内的突变部位的不稳定相互作用,并在突变者中破坏了功能终端区域的动态.
结论:
- 这种V762A突变增强了niraparib,rucaparib和talazoparib与PARP1的结合.
- 塔拉佐帕里布对V762A突变体的动态有明显的影响,可能会影响其催化活性和稳定性.
- 这些发现提供了关于PARP抑制剂在V762A PARP1变种癌症中的差异性疗效的见解.
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Mismatch Repair
4.8K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
4.8K
Epigenetic Regulation
3.0K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.0K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
DNA Damage can Stall the Cell Cycle
9.0K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.0K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K


